Atıf Formatları
Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

M. A. Brausi Et Al. , "Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer," EUROPEAN UROLOGY SUPPLEMENTS , vol.11, no.1, 2012

Brausi, M. A. Et Al. 2012. Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer. EUROPEAN UROLOGY SUPPLEMENTS , vol.11, no.1 .

Brausi, M. A., Oddens, J. R., Sylvester, R. J., Bono, A., Van de Beek, C., Van Andel, G., ... Gontero, P.(2012). Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer. EUROPEAN UROLOGY SUPPLEMENTS , vol.11, no.1.

Brausi, M. Et Al. "Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer," EUROPEAN UROLOGY SUPPLEMENTS , vol.11, no.1, 2012

Brausi, M. A. Et Al. "Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer." EUROPEAN UROLOGY SUPPLEMENTS , vol.11, no.1, 2012

Brausi, M. A. Et Al. (2012) . "Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer." EUROPEAN UROLOGY SUPPLEMENTS , vol.11, no.1.

@article{article, author={M. A. Brausi Et Al. }, title={Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer}, journal={EUROPEAN UROLOGY SUPPLEMENTS}, year=2012}